Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Regulation

Regulatory News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Advisory panels scheduled for HIV home-use test, transcatheter atrial septal occluders and MarginProbe intraoperative cancer detection system. More regulatory briefs.

You may also be interested in...



Warning Letter Cites Thoratec For Inadequate Response To A Patient Death

FDA outlines Thoratec's alleged late reporting and inadequate investigation of a patient death that may have been related to the HeartMate II left ventricular assist device.

News In Brief

OraSure completes in-home HIV assay submission. OIG report highlights problems with new DMEPOS enrollees. More news briefs.

Research In Brief

Breast cancer treatment data, study updates on bioresorbable stents and BMP-2, and more research news.

Table

View full table

Topics

Tags:
Medical Device Regulation
Latest Headlines

Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

See All
UsernamePublicRestriction

Register

MT031124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By